

Olaf Neumann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8466528/publications.pdf>

Version: 2024-02-01

26
papers

1,388
citations

516215

16
h-index

552369

26
g-index

26
all docs

26
docs citations

26
times ranked

2496
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. <i>Gut</i> , 2022, 71, 391-401.	6.1	21
2	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 303-313.	1.5	15
3	Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 551-560.	1.5	4
4	Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	23
5	Accurate and efficient detection of gene fusions from RNA sequencing data. <i>Genome Research</i> , 2021, 31, 448-460.	2.4	215
6	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. <i>Lung Cancer</i> , 2021, 154, 131-141.	0.9	8
7	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	7.7	125
8	Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. <i>European Journal of Cancer</i> , 2021, 157, 179-189.	1.3	13
9	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. <i>Oncogene</i> , 2020, 39, 814-832.	2.6	19
10	Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 787-791.	1.4	7
11	Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 406-416.	1.5	10
12	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. <i>International Journal of Cancer</i> , 2020, 146, 3053-3064.	2.3	14
13	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer – Results from a prospective pilot study using a 37 gene panel. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 637.e17-637.e27.	0.8	12
14	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. <i>Cancers</i> , 2019, 11, 1309.	1.7	32
15	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1935-1947.	0.5	69
16	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. <i>Cancers</i> , 2019, 11, 124.	1.7	36
17	Variant classification in precision oncology. <i>International Journal of Cancer</i> , 2019, 145, 2996-3010.	2.3	76
18	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. <i>International Journal of Cancer</i> , 2019, 145, 2963-2973.	2.3	24

#	ARTICLE	IF	CITATIONS
19	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and real-life analysis of three larger gene panels. <i>International Journal of Cancer</i> , 2019, 144, 2303-2312.	2.3	95
20	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. <i>International Journal of Cancer</i> , 2019, 145, 649-661.	2.3	85
21	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. <i>International Journal of Cancer</i> , 2019, 144, 848-858.	2.3	131
22	Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 3-11.	1.5	14
23	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	20
24	Implementing tumor mutational burden (TMB) analysis in routine diagnostics – a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	1.3	152
25	Protumorigenic role of Timeless in hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 597-606.	1.4	32
26	Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. <i>Hepatology</i> , 2012, 56, 1817-1827.	3.6	136